Adaptive Biotechnologies Corporation
ADPT
Kedudukan dalam Saham
#4180
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in... Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
Harga Saham
$23.89
Modal Pasaran
$3.81B
Perubahan (1 hari)
-0.27%
Perubahan (1 tahun)
33.96%
Negara
US
Perdagangan Adaptive Biotechnologies Corporation (ADPT)
Kategori
Healthcare
Bilangan saham terbitan bagi Adaptive Biotechnologies Corporation (ADPT)
Bilangan saham terbitan setakat June 2026: 157.70M
Menurut laporan kewangan terkini dan harga saham Adaptive Biotechnologies Corporation, bilangan saham terbitan semasa ialah 157.70M. Pada akhir December 2024, syarikat mempunyai 147.10M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Adaptive Biotechnologies Corporation (ADPT) dari 2017 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 157.70M | 3.94% |
| 2025 | 151.72M | 3.14% |
| 2024 | 147.10M | 1.88% |
| 2023 | 144.38M | 1.31% |
| 2022 | 142.52M | 1.54% |
| 2021 | 140.35M | 6.96% |
| 2020 | 131.22M | 5.53% |
| 2019 | 124.34M | 17.93% |
| 2018 | 105.43M | 0.00% |
| 2017 | 105.43M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 61.00% |
US
|
|
| 396.00M | 151.11% |
US
|
|
| 478.91M | 203.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -60.57% |
NL
|
